Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reached all time high today, Dec, 6 and still has $233.78 target or 5.00% above today’s $222.65 share price. This indicates more upside for the $57.25B company. This technical setup was reported by Barchart.com. If the $233.78 PT is reached, the company will be worth $2.86 billion more. The stock decreased 0.19% or $0.42 during the last trading session, reaching $222.65. About 341,142 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has declined 4.47% since December 6, 2018 and is downtrending. It has underperformed by 4.47% the S&P500. Some Historical VRTX News: 24/04/2018 – Vertex Provides Customer Platform to DC Water; 20/03/2018 – L-3’s Vertex draws Platinum Equity, Veritas, sources say [20:51 GMT20 Mar 2018] [Proprietary] []; 16/05/2018 – BSE Mumbai Bourse: Results from Vertex Securities for Apr 01 to Mar 31; 03/04/2018 – Vertex Announces Integration with Acumatica; 04/05/2018 – Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘sham’; 30/05/2018 – CRISPR, VERTEX CITES INDA FOR SICKLE CELL DISEASE TREATMENT; 30/05/2018 – CRISPR THERAPEUTICS AG – U.S FDA HAS PLACED A CLINICAL HOLD ON IND FOR CTX001 FOR TREATMENT OF SICKLE CELL DISEASE; 26/04/2018 – VERTEX 1Q SYMDEKO REV. $34M, EST. $32.5M; 04/04/2018 – Q-STATE BIOSCIENCES – VERTEX IS RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES RESULTING FROM COLLABORATION; 26/04/2018 – Vertex Pharma’s quarterly profit falls 15.1 percent

Gtt Communications Inc (NYSE:GTT) had an increase of 0.43% in short interest. GTT’s SI was 12.90M shares in December as released by FINRA. Its up 0.43% from 12.84 million shares previously. With 482,700 avg volume, 27 days are for Gtt Communications Inc (NYSE:GTT)’s short sellers to cover GTT’s short positions. The SI to Gtt Communications Inc’s float is 32.25%. The stock decreased 0.10% or $0.01 during the last trading session, reaching $10.51. About 332,416 shares traded. GTT Communications, Inc. (NYSE:GTT) has declined 72.37% since December 6, 2018 and is downtrending. It has underperformed by 72.37% the S&P500. Some Historical GTT News: 17/04/2018 – S&P: GTT COMMUNICATIONS ‘B’ CORPORATE CREDIT RATING AFFIRMED;; 26/04/2018 – GTT Announces Earnings Call for First Quarter 2018; 27/03/2018 – GTT WINS SAMSUNG HEAVY INDUSTRIES TO DESIGN LNG TANKS; 17/04/2018 – S&P: GTT’s Negative Outlook Reflects Pro Forma Adjusted Leverage That Is Currently Elevated for the Rating; 21/03/2018 – GTT GTT.PA – DELIVERY IS EXPECTED IN 2020; 03/05/2018 – GTT Communications 1Q Rev $260.7M; 26/04/2018 – Fitch Affirms GTT Communications’ IDR at ‘B’ On Term Loan Upsizing; Downgrades Sr Secured Ratings; 16/05/2018 – GTT GETS NOTIFICATION FOR ORDER OF 2 NEW LNG CARRIERS; 30/05/2018 – REG-GTT: Main terms and conditions of the share buy-back programme; 26/04/2018 – REG-GTT : NOTICE OF AVAILABILITY OF THE 2017 REGISTRATION DOCUMENT

More notable recent GTT Communications, Inc. (NYSE:GTT) news were published by: Businesswire.com which released: “GTT Completes Acquisition of KPN International – Business Wire” on December 02, 2019, also Seekingalpha.com with their article: “GTT Communications Q3 Earnings Preview – Seeking Alpha” published on November 11, 2019, Fool.com published: “Why GTT Communications Stock Plunged Today – Motley Fool” on November 12, 2019. More interesting news about GTT Communications, Inc. (NYSE:GTT) were released by: Benzinga.com and their article: “Two Retailers Among Top Charts To Watch – Benzinga” published on December 06, 2019 as well as Fool.com‘s news article titled: “Why GTT Communications Stock Popped Today – The Motley Fool” with publication date: November 27, 2019.

Among 2 analysts covering GTT Communications (NYSE:GTT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GTT Communications has $40 highest and $900 lowest target. $24.50’s average target is 133.11% above currents $10.51 stock price. GTT Communications had 5 analyst reports since June 24, 2019 according to SRatingsIntel. The company was maintained on Friday, August 9 by SunTrust. Craig Hallum maintained GTT Communications, Inc. (NYSE:GTT) on Monday, June 24 with “Buy” rating.

GTT Communications, Inc. provides cloud networking services to multinational enterprises, carriers, and government clients worldwide. The company has market cap of $627.00 million. It offers private, public, and hybrid cloud network solutions; high bandwidth-Internet connectivity and IP transit, as well as broadband and wireless access services; managed equipment, security, and remote access services; and voice and unified communications services consisting of SIP trunking and enterprise PBX services. It currently has negative earnings. The companyÂ’s IP network consists of approximately 250 points of presence.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $57.25 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 27.02 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Among 16 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 15 have Buy rating, 0 Sell and 1 Hold. Therefore 94% are positive. Vertex Pharmaceuticals has $25400 highest and $203 lowest target. $229.56’s average target is 3.10% above currents $222.65 stock price. Vertex Pharmaceuticals had 30 analyst reports since August 1, 2019 according to SRatingsIntel. On Thursday, August 1 the stock rating was maintained by Credit Suisse with “Outperform”. The firm earned “Overweight” rating on Thursday, August 1 by Piper Jaffray. The rating was maintained by Leerink Swann on Tuesday, October 22 with “Hold”. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, August 1. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by RBC Capital Markets on Thursday, October 31. Piper Jaffray maintained the shares of VRTX in report on Thursday, October 24 with “Buy” rating. BMO Capital Markets maintained the shares of VRTX in report on Monday, October 21 with “Buy” rating. The stock has “Overweight” rating by Morgan Stanley on Thursday, October 31. Piper Jaffray maintained it with “Overweight” rating and $24700 target in Thursday, October 31 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Stifel Nicolaus on Thursday, October 31.

Investors sentiment increased to 1.31 in 2019 Q3. Its up 0.14, from 1.17 in 2019Q2. It is positive, as 37 investors sold Vertex Pharmaceuticals Incorporated shares while 166 reduced holdings. 62 funds opened positions while 204 raised stakes. 234.70 million shares or 0.28% less from 235.36 million shares in 2019Q2 were reported. Ameritas Invest Incorporated owns 17,139 shares. Moreover, Dekabank Deutsche Girozentrale has 0.24% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 233,034 shares. Huntington Savings Bank accumulated 602 shares. Exane Derivatives has invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Oregon Public Employees Retirement Fund holds 0.06% or 25,884 shares in its portfolio. Panagora Asset Mngmt holds 0.2% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 260,820 shares. The Wisconsin-based Dana Invest Advisors has invested 0.12% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Adirondack Co holds 0% or 25 shares. Azimuth Management Lc reported 52,715 shares. Daiwa Secs stated it has 0.02% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Kelly Lawrence W & Assocs Incorporated Ca holds 8,823 shares or 0.25% of its portfolio. Bailard Inc has invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Sector Pension Inv Board holds 0.06% or 49,955 shares in its portfolio. Guggenheim Capital Lc holds 233,682 shares or 0.29% of its portfolio. Oppenheimer has invested 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on February, 4. They expect $0.95 EPS, down 5.00% or $0.05 from last year’s $1 per share. VRTX’s profit will be $244.29M for 58.59 P/E if the $0.95 EPS becomes a reality. After $0.97 actual EPS reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -2.06% negative EPS growth.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link